Compare NEXN & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXN | CAPR |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.2M | 324.6M |
| IPO Year | 2021 | N/A |
| Metric | NEXN | CAPR |
|---|---|---|
| Price | $6.85 | $26.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $12.13 | ★ $37.75 |
| AVG Volume (30 Days) | 366.1K | ★ 5.8M |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 237.45 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $376,353,000.00 | $11,130,509.00 |
| Revenue This Year | $5.43 | N/A |
| Revenue Next Year | N/A | $7,736.03 |
| P/E Ratio | $10.75 | ★ N/A |
| Revenue Growth | ★ 7.80 | N/A |
| 52 Week Low | $6.08 | $4.30 |
| 52 Week High | $12.60 | $40.37 |
| Indicator | NEXN | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 72.19 |
| Support Level | $6.45 | $25.59 |
| Resistance Level | $6.75 | $29.23 |
| Average True Range (ATR) | 0.21 | 3.28 |
| MACD | 0.11 | 1.31 |
| Stochastic Oscillator | 67.56 | 62.63 |
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.